Olaparib Combined with Anti-PD1 Enhances Immunotherapy of Gastric Cancer Via NF-κB/c-Myc/PD-L1 Signaling
Olaparib activates the NF-κB/c-MYC pathway to elevate PD-L1, supporting its combination with PD-1 inhibitors as a promising GC therapeutic strategy.
Authors
- Zhongqi Ge (ORCID: https://orcid.org/0000-0002-8155-5088)
- Wubin Zheng
- Yongjun Nai
- Huajing Wan (ORCID: https://orcid.org/0000-0002-6041-8877)
- Junjie Sun (ORCID: https://orcid.org/0000-0001-8710-7318)
- Chengyu Lv (ORCID: https://orcid.org/0009-0009-0028-4166)
- Qingwei Wu (ORCID: https://orcid.org/0000-0002-5654-327X)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1007/s10620-025-09021-y
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05